Nebenwirkungen · Voncento
Voncento 250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion Voncento 500 IU FVIII /1200 IU VWF (10 ml solvent) powder and solvent for solution for injection/infusion Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion Voncento 1000 IU FVIII / 2400 IU VWF (10 ml solvent) powder and solvent for solution for injection/infusion · Abschnitt 4.8 · PDF-Seite 9
HOS-126410 · Präparat HOS-096255
VWF inhibition Not known*** Immune system disorders Hypersensitivity (including Common tachycardia, chest pain, chest discomfort and back pain) Nervous system disorders Dysgeusia Uncommon Vascular disorders Thromboembolic event Uncommon General disorders and Pyrexia Common administration site conditions Headache Very common Investigations Liver function test abnormal Uncommon * Adverse events assessed as related to administration of the Voncento **Frequency is based on studies with all FVIII products which included patients with severe haemophilia A. PTPs = previously-treated patients, PUPs = previously-untreated patients. *** Observed during postmarketing surveillance, not observed in clinical trials.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T10:27:00Z · SHA-256 ca1ae0f77c8e50bac06f88884e4c5441c2001b4c318f941dc0710c94f568d539 · Passage 56071d579a320f07f5dc30b913c8110b4054383d1e10d98e5e6e097dd8dc40b0 · Zeichen 1156–2144 im Abschnitt